氨基水杨酸类药物或硫嘌呤类药物对炎症性肠病结直肠癌风险的影响
在CESAME观察性队列中嵌套的病例对照研究,纳入144例发生结直肠癌的炎症性肠病患者和286例匹配对照,评估氨基水杨酸类或硫嘌呤类药物暴露与结直肠癌风险的关系。多因素分析显示,氨基水杨酸类暴露与结直肠癌风险显著降低相关(OR=0.587,95%CI:0.367-0.937,P=0.0257),而硫嘌呤类暴露未显示显著关联(OR=0.762,95%CI:0.432-1.343,P=0.3468)。
要点
- 氨基水杨酸类暴露与炎症性肠病结直肠癌风险显著降低相关(OR=0.587,95%CI:0.367-0.937,P=0.0257)。
- 硫嘌呤类暴露与结直肠癌风险无显著关联(OR=0.762,95%CI:0.432-1.343,P=0.3468)。
- 研究为嵌套于CESAME观察性队列的病例对照研究,共144例病例和286例对照。
核心结论
- 在嵌套于CESAME队列的病例对照研究中,炎症性肠病患者氨基水杨酸类暴露与结直肠癌风险显著降低相关,而硫嘌呤类暴露未显示显著关联。
研究设计与样本
- 病例对照研究嵌套于CESAME观察性队列,该队列在2004年5月至2005年6月间连续纳入炎症性肠病患者,随访至2007年12月。
- 研究人群包括144例从炎症性肠病诊断后发生结直肠癌的病例患者(其中65例在2004年前诊断,79例自2004年即CESAME前瞻性观察期开始年份起诊断)和286例对照,对照按性别、年龄、炎症性肠病亚型和诊断年份以及结肠炎累积范围匹配。
- 氨基水杨酸类或硫嘌呤类暴露定义为在癌症诊断当年接受该治疗。
- 接受5-氨基水杨酸和硫嘌呤的倾向性通过综合考虑患者和炎症性肠病特征的综合评分量化。
- 通过多因素分析评估氨基水杨酸类或硫嘌呤类的作用,倾向性评分和原发性硬化性胆管炎病史纳入多因素模型进行调整。
主要发现
- 经倾向性调整的多因素分析,癌症当年药物暴露对氨基水杨酸类显示显著保护作用(OR=0.587,95%CI:0.367-0.937,P=0.0257)。
- 经倾向性调整的多因素分析,癌症当年药物暴露对硫嘌呤类未显示显著保护作用(OR=0.762,95%CI:0.432-1.343,P=0.3468)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether aminosalicylates or thiopurines reduce the risk of colorectal cancer (CRC) in inflammatory bowel (IBD) disease is controversial. AIM: To assess simultaneously the chemopreventive effect of aminosalicylates or thiopurines in a case-control study nested in the CESAME observational cohort that enrolled consecutive patients with IBD between May 2004 and June 2005. Patients were followed up to December 2007. METHODS: Study population comprised 144 case patients who developed CRC from the diagnosis of IBD (65 and 79 cases diagnosed, respectively, before and from 2004, starting year of the prospective observational period of CESAME) and 286 controls matched for gender, age, IBD subtype and year of diagnosis, and cumulative extent of colitis. Exposure to aminosalicylates or thiopurines was defined by an exposure to the treatment during the year of the diagnosis of cancer. The propensity of receiving 5-ASA and thiopurines was quantified by a composite score taking into account patient and IBD characteristics. The role of aminosalicylates or thiopurines was assessed by multivariate analysis. Propensity scores and the history of primary sclerosing cholangitis were entered into the multivariate model for adjustment. RESULTS: By multivariate analysis adjusted for propensity, a significant protective effect of exposure to drugs during the year of cancer was found for aminosalicylates (OR = 0.587, 95% CI: 0.367-0.937, P = 0.0257), but not for thiopurines (OR = 0.762, 95% CI: 0.432-1.343, P = 0.3468). CONCLUSION: In a case-control study nested in the CESAME cohort, a significant decrease in the risk of colorectal cancer in IBD was associated with exposure to aminosalicylates, not to thiopurines.
引用
- Carrat F, Seksik P, Colombel JF, et al. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2016. PMID: 27995656. doi:10.1111/apt.13897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。